Knights of Columbus Asset Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Knights of Columbus Asset Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-19,074	Closed	-$3.04M	–	370
2022 Q4	$3.04M	Buy	+19,074	New	+$2.8M	0.32%	105
2021 Q2	–	Sell	-12,684	Closed	-$2.08M	–	325
2021 Q1	$2.08M	Buy	12,684 +414	+3%	+$68.1K	0.2%	176
2020 Q4	$2.02M	Buy	12,270 +503	+4%	+$74.9K	0.22%	166
2020 Q3	$1.68M	Sell	11,767 -1,252	-10%	-$155K	0.21%	162
2020 Q2	$1.44M	Hold	13,019	–	–	0.18%	182
2020 Q1	$1.3M	Sell	13,019 -1,103	-8%	-$143K	0.16%	188
2019 Q4	$2.11M	Buy	14,122 +11,051	+360%	+$1.5M	0.19%	180
2019 Q3	$394K	Sell	3,071 -2,818	-48%	-$378K	0.15%	117
2019 Q2	$840K	Sell	5,889 -1,330	-18%	-$179K	0.33%	89
2019 Q1	$1.03M	Buy	7,219 +622	+9%	+$81.1K	0.42%	78
2018 Q4	$818K	Buy	6,597 +718	+12%	+$107K	0.37%	89
2018 Q3	$988K	Buy	+5,879	New	+$1.01M	0.4%	83

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Knights of Columbus Asset Advisors's JAZZ Position: Q1 2023 in Review

Knights of Columbus Asset Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2023, closing a stake of 19,074 shares — an estimated $3.04M sold.

Knights of Columbus Asset Advisors first reported a position in JAZZ in Q3 2018 and held it in 12 quarters. The position peaked at $3.04M in Q4 2022. 471 funds tracked by Wall St. Rank hold JAZZ as of Q1 2023.

Knights of Columbus Asset Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Knights of Columbus Asset Advisors sold 19,074 Jazz Pharmaceuticals shares in Q1 2023, an estimated $3.04M.
Knights of Columbus Asset Advisors first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 12 quarters.
Knights of Columbus Asset Advisors's Jazz Pharmaceuticals position peaked at $3.04M in Q4 2022.
471 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2023.

Based on Knights of Columbus Asset Advisors's 13F filing for Q1 2023, filed 1 May 2023.